Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Eva Divíšková"'
Autor:
Jana Kotašková, Ondrej Letocha, Barbara Kantorová, Jitka Kabáthová, Michael Doubek, Eva Vavrova, Šárka Pospíšilová, Jiri Mayer, Barbara Vonková, Hana SkuhrováFrancová, Eva Divíšková, Yvona Brychtová
Publikováno v:
Leukemia research. 60
The hotspot c.7541_7542delCT NOTCH1 mutation has been proven to have a negative clinical impact in chronic lymphocytic leukemia (CLL). However, an optimal method for its detection has not yet been specified. The aim of our study was to examine the pr
Autor:
Petra Šmuhařová, Eva Divíšková, Vladimíra Vallová, Lenka Tomášiková, Veronika Némethová, Alexandra Oltová, Michael Doubek, Jiří Mayer, Gabriela Vaňková, Šárka Pospíšilová, Kristina Štěpanovská, Karla Plevová, Petr Kuglík
Publikováno v:
Europe PubMed Central
Background Chromosomal aberrations play an important role as prognostic factors in chronic lymphocytic leukemia (CLL). These aberrations are mostly detected by fluorescent in situ hybridization (FISH), as chromosomal banding analysis has been scarce
Publikováno v:
Geomicrobiology Journal. 30:1-7
Cellular ATP content of Acidithiobacillus ferrooxidans cultures was determined with a bioluminescence assay in relation to batch growth and oxidation of ferrous iron and elemental sulfur. Inhibitory effects of inorganic substrates and products on luc
Autor:
Jana Šmardová, Martin Trbušek, Marek Borsky, Kamila Brázdilová, Veronika Navrkalová, Barbara Kantorová, Šárka Pospíšilová, Michael Doubek, Eva Divíšková, Lenka Radová, Nikola Tom, Hana Skuhrová Francová, Jiri Mayer, Karla Plevová, Yvona Brychtová, Jitka Malčíková
Publikováno v:
British journal of haematology. 178(6)
The clinical course in chronic lymphocytic leukaemia (CLL) patients is diverse, reflecting the heterogeneous biological background of this disease (Guieze & Wu, 2015). Among reported defects, mutations in NOTCH1 and TP53 genes represent potent CLL pr
Autor:
Eva Divíšková, Jan Novák, Petr Jedelský, Břetislav Brzobohatý, Martin Černý, Jana Baldrianová
Publikováno v:
Journal of Proteomics
Karrikins are butenolide plant growth regulators in smoke from burning plant material that have proven ability to promote germination and seedling photomorphogenesis. However, the molecular mechanisms underlying these processes are unclear. Here we p
Autor:
Alexandra Oltová, Sim Truong, Jana Kotašková, Jana Šmardová, Jiri Mayer, Boris Tichy, Jitka Malčíková, Šárka Pospíšilová, Nancy Patten, Šárka Pavlová, Karla Plevová, Eva Divíšková, Nikola Tom, Michael Doubek, Martin Trbušek, Yvona Brychtová, Barbara Kantorová
Publikováno v:
Tumor Biology
TP53 gene defects represent a strong adverse prognostic factor for patient survival and treatment resistance in chronic lymphocytic leukemia (CLL). Although various methods for TP53 mutation analysis have been reported, none of them allow the identif
Autor:
Veronika Navrkalová, Michael Doubek, Karla Plevová, Alexandra Oltová, Marek Borsky, Jitka Malčíková, Eva Divíšková, Nikola Tom, Jana Šmardová, Barbara Kantorová, Kamila Brázdilová, Karol Pál, Jiri Mayer, Šárka Pavlová, Martin Trbušek, Yvona Brychtová, Šárka Pospíšilová
Publikováno v:
Blood. 124:3283-3283
Introduction A presence of activating mutations in NOTCH1 gene has been recently associated with reduced survival and chemo-immunotherapy resistance in chronic lymphocytic leukemia (CLL). However, a prognostic significance of the NOTCH1 mutations wit
Publikováno v:
New Biotechnology. 29:S234
Aplikovali jsme kit pro stanoveni ATP v kulturach bakterii Acidithiobacillus ferrooxidans, aby se monitoroval růst buněk a jejich metabolicka aktivita.
Autor:
Martin Trbušek, Barbara Kantorová, Eva Divíšková, Jana Šmardová, Yvona Brychtová, Šárka Pospíšilová, Katerina Stano-Kozubik, Nikola Tom, Boris Tichy, Jitka Malčíková, Šárka Pavlová, Michael Doubek, Lenka Radová, Jiří Mayer, Alexandra Oltová, Karla Plevová, Filip Pardy, Marek Mráz
Publikováno v:
Leukemia
In chronic lymphocytic leukemia (CLL), the worst prognosis is associated with TP53 defects with the affected patients being potentially directed to alternative treatment. Therapy administration was shown to drive the selection of new TP53 mutations i